Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
X4 Pharmaceuticals announces inducement grants under Nasdaq listing rule » 08:18
07/01/20
07/01
08:18
07/01/20
08:18
XFOR

X4 Pharmaceuticals

$9.25 /

+0.73 (+8.57%)

X4 Pharmaceuticals…

X4 Pharmaceuticals announced that, on June 30, 2020, the Compensation Committee of X4's Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan. The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 15,200 shares of X4's common stock and were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and an exercise price of $9.32 per share, which is equal to the closing price of X4's common stock on June 30, 2020. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee's continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$9.25 /

+0.73 (+8.57%)

XFOR X4 Pharmaceuticals
$9.25 /

+0.73 (+8.57%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XFOR X4 Pharmaceuticals
$9.25 /

+0.73 (+8.57%)

  • 26
    Nov
Over a week ago
Conference/Events
X4 Pharmaceuticals management to meet virtually with Needham » 04:55
06/22/20
06/22
04:55
06/22/20
04:55
XFOR

X4 Pharmaceuticals

$9.90 /

+0.16 (+1.64%)

Virtual Meeting to be…

Virtual Meeting to be held on June 22 hosted by Needham.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$9.90 /

+0.16 (+1.64%)

XFOR X4 Pharmaceuticals
$9.90 /

+0.16 (+1.64%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XFOR X4 Pharmaceuticals
$9.90 /

+0.16 (+1.64%)

Conference/Events
X4 Pharmaceuticals management to meet virtually with Needham » 12:36
06/18/20
06/18
12:36
06/18/20
12:36
XFOR

X4 Pharmaceuticals

$9.88 /

-0.035 (-0.35%)

Virtual Meeting to be…

Virtual Meeting to be held on June 22 hosted by Needham.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$9.88 /

-0.035 (-0.35%)

XFOR X4 Pharmaceuticals
$9.88 /

-0.035 (-0.35%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XFOR X4 Pharmaceuticals
$9.88 /

-0.035 (-0.35%)

Conference/Events
Oppenheimer to hold a virtual event » 08:41
06/15/20
06/15
08:41
06/15/20
08:41
XFOR

X4 Pharmaceuticals

$8.59 /

+0.62 (+7.78%)

Healthcare Analysts hold…

Healthcare Analysts hold a virtual event entitled, "Emerging Healthcare Series" on June 15.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$8.59 /

+0.62 (+7.78%)

XFOR X4 Pharmaceuticals
$8.59 /

+0.62 (+7.78%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XFOR X4 Pharmaceuticals
$8.59 /

+0.62 (+7.78%)

Recommendations
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital » 11:58
06/12/20
06/12
11:58
06/12/20
11:58
XFOR

X4 Pharmaceuticals

$7.91 /

-0.06 (-0.75%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah said the data from the Phase 2 expansion and extension studies for mavorixafor presented at the EHA meeting by X4 continue to support the potential of the drug to lessen healthcare resource utilization. The data further boost her confidence in the Phase 3 study, added Jallah, who has a Buy rating on X4 shares.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$7.91 /

-0.06 (-0.75%)

XFOR X4 Pharmaceuticals
$7.91 /

-0.06 (-0.75%)

03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
01/07/20 H.C. Wainwright
X4 Pharmaceuticals initiated with a Buy at H.C. Wainwright
XFOR X4 Pharmaceuticals
$7.91 /

-0.06 (-0.75%)

Conference/Events
X4 Pharmaceuticals to hold a pharmaceutical update conference call » 08:25
06/12/20
06/12
08:25
06/12/20
08:25
XFOR

X4 Pharmaceuticals

$7.97 /

-0.67 (-7.75%)

Management discusses new…

Management discusses new clinical efficacy and safety data from the Company's ongoing Phase 2 open-label extension trial of its lead candidate, Mavorixafor, in patients with WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome on a conference call to be held on June 12 at 8:30 am. Webcast Link

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
01/07/20 H.C. Wainwright
X4 Pharmaceuticals initiated with a Buy at H.C. Wainwright
XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

Hot Stocks
X4 Pharmaceuticals presents clinical data from mavorixafor Phase 2 study » 06:20
06/12/20
06/12
06:20
06/12/20
06:20
XFOR

X4 Pharmaceuticals

$7.97 /

-0.67 (-7.75%)

X4 Pharmaceuticals…

X4 Pharmaceuticals presented positive biomarker, efficacy, and safety data from its ongoing Phase 2 open-label extension trial of its lead candidate, mavorixafor, in patients with warts, hypogammaglobulinemia, infections, and myelokathexis, or WHIM, syndrome. X4 said in a release, "The results included significant reductions in yearly infection rates and wart burden in WHIM patients treated for at least six months with mavorixafor. The data were presented in an e-poster at the 25th European Hematology Association, or EHA, Annual Congress, taking place virtually from June 11-14." Paula Ragan, Ph.D., President and CEO of X4 Pharmaceuticals said, "We are extremely encouraged by the positive therapeutic profile of mavorixafor emerging from this study, including improvements in key biomarkers and clinical symptoms at the higher doses. These results suggest that mavorixafor is a promising, disease-modifying therapy that, by down-regulating CXCR4/CXCL12 signaling, could lead to improved and durable clinical efficacy in patients with WHIM syndrome. We view these data as a significant de-risking event for our ongoing and pivotal Phase 3 clinical trial, from which we expect top-line data in 2022. We look forward to continuing to advance the development of mavorixafor for patients with WHIM syndrome, a rare disease that we estimate could affect more than 3,500 people in the United States and that has no currently approved treatments." The company added, "The original Phase 2 clinical trial was an open-label, dose-escalation study that was followed by an open-label extension study to assess the safety, tolerability, dose-response, and clinical impact of mavorixafor in adult patients with genetically confirmed WHIM syndrome. The extension phase was open to patients who completed at least 24 weeks of the initial dose-escalation study and explored additional endpoints related to absolute neutrophil and lymphocyte counts, infection rates and wart burden, as well as long-term safety."

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
01/07/20 H.C. Wainwright
X4 Pharmaceuticals initiated with a Buy at H.C. Wainwright
XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

Conference/Events
X4 Pharmaceuticals to hold a pharmaceutical update conference call » 04:55
06/12/20
06/12
04:55
06/12/20
04:55
XFOR

X4 Pharmaceuticals

$7.97 /

-0.67 (-7.75%)

Management discusses new…

Management discusses new clinical efficacy and safety data from the Company's ongoing Phase 2 open-label extension trial of its lead candidate, Mavorixafor, in patients with WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome on a conference call to be held on June 12 at 8:30 am. Webcast Link

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
01/07/20 H.C. Wainwright
X4 Pharmaceuticals initiated with a Buy at H.C. Wainwright
XFOR X4 Pharmaceuticals
$7.97 /

-0.67 (-7.75%)

Hot Stocks
X4 Pharmaceuticals promotes Renato Skerlj to CSO » 08:16
06/11/20
06/11
08:16
06/11/20
08:16
XFOR

X4 Pharmaceuticals

$8.64 /

-0.67 (-7.20%)

X4 Pharmaceuticals…

X4 Pharmaceuticals announced the promotion of Renato Skerlj, Ph.D., to the position of chief scientific officer. Dr. Skerlj is one of the scientific founders of X4 and co-inventor of X4's lead drug candidate, mavorixafor. He joined the company in September 2019 as Senior Vice President, Research and Development. As chief scientific officer, Dr. Skerlj will lead all research and development functions and pre-clinical development activities.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$8.64 /

-0.67 (-7.20%)

XFOR X4 Pharmaceuticals
$8.64 /

-0.67 (-7.20%)

03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
01/07/20 H.C. Wainwright
X4 Pharmaceuticals initiated with a Buy at H.C. Wainwright
XFOR X4 Pharmaceuticals
$8.64 /

-0.67 (-7.20%)

Conference/Events
X4 Pharmaceuticals to hold a pharmaceutical update conference call » 16:15
06/09/20
06/09
16:15
06/09/20
16:15
XFOR

X4 Pharmaceuticals

$9.31 /

-0.17 (-1.79%)

Management discusses new…

Management discusses new clinical efficacy and safety data from the Company's ongoing Phase 2 open-label extension trial of its lead candidate, Mavorixafor, in patients with WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome on a conference call to be held on June 12 at 8:30 am. Webcast Link

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$9.31 /

-0.17 (-1.79%)

XFOR X4 Pharmaceuticals
$9.31 /

-0.17 (-1.79%)

03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
01/07/20 H.C. Wainwright
X4 Pharmaceuticals initiated with a Buy at H.C. Wainwright
XFOR X4 Pharmaceuticals
$9.31 /

-0.17 (-1.79%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.